What We're Reading: Page 345
Industry reads hand-picked by our editors
Jun 03, 2016
-
EP Vantage
Strimvelis approval could rejuvenate gene therapy arena
-
Washington Post
Stanford researchers ‘stunned’ by stem cell experiment that helped stroke patient walk
-
Bloomberg
Valeant Gets Default Notice Due to Quarterly Filing Delay
-
Reuters
Botswana gets GSK's modern HIV drug in largest ever Africa tender
Jun 02, 2016
Jun 01, 2016
May 31, 2016
-
Reuters
Roche and Novartis face off in biosimilar drug battle
-
Chicago Tribune
Shareholders approve $32 billion Baxalta-Shire merger
-
New York Times
Emmanuelle Charpentier's Still-Busy Life After Crispr
-
Wall Street Journal
FDA Asks Teva for More Information on Huntington’s Drug
May 27, 2016
May 26, 2016
-
Bloomberg
Celgene, Gilead Said to Join Suitors Mulling Medivation Bids
-
New York Times
Could Alzheimer's Stem From Infections? It Makes Sense, Experts Say
-
BioCentury
Sen. Alexander opposes FDA funding surge
-
International Business Times
Healthcare And Pharma CEOs Paid More Than Top Execs In Any Other Industry, Analysis Finds
May 25, 2016
-
Wall Street Journal
SEC Reviewed Valeant’s Use of ‘Non-GAAP’ Financial Measures
-
Reuters
Lilly says new type of pain drug could lessen need for opioids
-
Economic Times
Delhi High Court asks Roche to explain lawsuit over Avastin copy
-
Stat
There’s just one female CEO among San Diego’s public biotechs. Here’s why
Previous
